Last reviewed · How we verify
INDV-2000
At a glance
| Generic name | INDV-2000 |
|---|---|
| Also known as | C4X_3256 |
| Sponsor | Indivior Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Somnolence
- Vessel puncture site pain
- Dizzines
- Gastroenteritis
- Skin lacerations
- Headache
- Presyncope
- Blood creatine phosphokinase increased
- Alanine aminotransferase increased
- Aspartate aminotransferase increased
- Blood bilirubin increased
- Blood pressure diastolic increased
Key clinical trials
- Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder (PHASE2)
- Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder (PHASE1)
- Study of Potential CYP3A4 Induction by INDV-2000 in Healthy Adults (PHASE1)
- INDV-2000 First in Human (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |